Category Archives: AZBio News

Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at Risk for Preterm Births

Posted on by

TUCSON, AZ / ACCESSWIRE / September 22, 2020 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation in patients with serious acute and chronic diseases, has been awarded a one year NIH FAST-TRACK AWARD (1R41 HD101202-01A1) to support development of a humanized antibody therapy for pregnant women with intrauterine infection at risk for preterm birth.Continue reading→

C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease

Posted on by

September is National Sickle Cell Awareness Month

TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.Continue reading→

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Posted on by

– Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points

– Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo–a 72 percent risk reduction in this limited population

– LY-CoV555 was well-tolerated across all doses with no drug-related serious adverse events reported
INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2 neutralizing antibody, for the treatment of symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups (placebo, 700 mg, 2800 mg, and 7000 mg).Continue reading→

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

Posted on by
  • Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment –
  • New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs
  • More sensitive than traditional Pap cytology, this test allows clinicians to determine which HPV-positive women require further diagnostic procedures to prevent disease progression

Continue reading→